Scientists prevail in Johnson & Johnson talc case
A US federal judge has rejected Johnson & Johnson’s trade libel case against three scientists whose research linked cosmetic talc exposure to mesothelioma, ruling that the company failed to show the researchers acted with actual malice.
US District Judge Jamar K. Walker granted summary judgment to doctors Theresa Emory, John Maddox and Richard Kradin in the Eastern District of Virginia, ending the remaining claim in litigation brought by Johnson & Johnson subsidiary Pecos River Talc LLC. The company has said it plans to appeal and seek a trial over what it describes as false statements concerning talc and asbestos exposure.
The dispute centred on a scientific paper published in March 2020 in the American Journal of Industrial Medicine. The researchers presented a case series involving 75 people with malignant mesothelioma whose only known exposure to asbestos, the paper said, was through cosmetic talc. The group was described as additional to 33 patients covered by an earlier study.
Johnson & Johnson challenged the accuracy of those representations. Evidence developed during the litigation showed that eight of the 75 patients had also appeared in the earlier study, contradicting the description of the group as entirely additional. The company also argued that some patients had possible asbestos exposure from sources other than cosmetic talc.
Walker found that mistakes had occurred in the underlying data but concluded that the record did not establish the legal standard required for trade libel. Pecos River had to produce clear and convincing evidence that the scientists published statements they knew were false or acted with reckless disregard for their truth.
The judge determined that the company had not created a genuine dispute of material fact on actual malice. The researchers had compared anonymised patient data and information supplied through lawyers, circumstances that could make duplicate cases difficult to identify. The court found no evidence showing that errors apparent during later litigation had been obvious to the researchers when the study was prepared.
The decision is significant beyond the immediate talc dispute because it addresses the boundary between corporate litigation and scientific publication. The researchers’ lawyers argued that allowing defamation-style claims to proceed without evidence of deliberate or reckless falsehood could have a chilling effect on researchers studying products that are already the subject of major litigation.
Johnson & Johnson takes the opposite view. It has maintained that the scientific literature used against the company in talc lawsuits contains serious flaws and that expert witnesses working with plaintiffs’ lawyers have helped create misleading claims about its products. The company has repeatedly said its cosmetic talc was safe, asbestos-free and did not cause cancer.
The Virginia case formed part of a broader legal strategy challenging experts involved in talc litigation. Johnson & Johnson also pursued separate litigation against Jacqueline Moline, whose earlier research examined mesothelioma cases associated with cosmetic talc. A federal judge in New Jersey dismissed that case in 2024, finding that the challenged research did not support the company’s allegations of fraud or libel.
The latest ruling does not establish that cosmetic talc causes mesothelioma, nor does it resolve the wider scientific debate over asbestos contamination and cancer risk. Its immediate legal finding is narrower: the company did not present sufficient evidence that Emory, Maddox and Kradin published their disputed statements with the level of knowledge or recklessness required to sustain the trade libel claim.
Mesothelioma is an aggressive cancer affecting the lining surrounding organs, most commonly the lungs, and asbestos exposure is its principal established cause. Litigation involving cosmetic talc has focused heavily on allegations that some talc deposits or finished products contained asbestos fibres. Johnson & Johnson has consistently disputed claims that its products contained asbestos.
The ruling arrives as the company seeks to reduce its exposure to more than a decade of talc litigation. Johnson & Johnson announced in July a proposed settlement committing at least $5.5 billion to resolve about 76,000 ovarian cancer claims. The agreement requires participation by firms representing at least 95 per cent of the remaining claims before it can take effect.
The settlement follows three unsuccessful attempts to resolve large numbers of talc claims through bankruptcy proceedings involving subsidiaries. A bankruptcy judge rejected the latest restructuring plan in 2025, after which Johnson & Johnson returned to defending cases individually while pursuing challenges to plaintiffs’ expert testimony.
US District Judge Jamar K. Walker granted summary judgment to doctors Theresa Emory, John Maddox and Richard Kradin in the Eastern District of Virginia, ending the remaining claim in litigation brought by Johnson & Johnson subsidiary Pecos River Talc LLC. The company has said it plans to appeal and seek a trial over what it describes as false statements concerning talc and asbestos exposure.
The dispute centred on a scientific paper published in March 2020 in the American Journal of Industrial Medicine. The researchers presented a case series involving 75 people with malignant mesothelioma whose only known exposure to asbestos, the paper said, was through cosmetic talc. The group was described as additional to 33 patients covered by an earlier study.
Johnson & Johnson challenged the accuracy of those representations. Evidence developed during the litigation showed that eight of the 75 patients had also appeared in the earlier study, contradicting the description of the group as entirely additional. The company also argued that some patients had possible asbestos exposure from sources other than cosmetic talc.
Walker found that mistakes had occurred in the underlying data but concluded that the record did not establish the legal standard required for trade libel. Pecos River had to produce clear and convincing evidence that the scientists published statements they knew were false or acted with reckless disregard for their truth.
The judge determined that the company had not created a genuine dispute of material fact on actual malice. The researchers had compared anonymised patient data and information supplied through lawyers, circumstances that could make duplicate cases difficult to identify. The court found no evidence showing that errors apparent during later litigation had been obvious to the researchers when the study was prepared.
The decision is significant beyond the immediate talc dispute because it addresses the boundary between corporate litigation and scientific publication. The researchers’ lawyers argued that allowing defamation-style claims to proceed without evidence of deliberate or reckless falsehood could have a chilling effect on researchers studying products that are already the subject of major litigation.
Johnson & Johnson takes the opposite view. It has maintained that the scientific literature used against the company in talc lawsuits contains serious flaws and that expert witnesses working with plaintiffs’ lawyers have helped create misleading claims about its products. The company has repeatedly said its cosmetic talc was safe, asbestos-free and did not cause cancer.
The Virginia case formed part of a broader legal strategy challenging experts involved in talc litigation. Johnson & Johnson also pursued separate litigation against Jacqueline Moline, whose earlier research examined mesothelioma cases associated with cosmetic talc. A federal judge in New Jersey dismissed that case in 2024, finding that the challenged research did not support the company’s allegations of fraud or libel.
The latest ruling does not establish that cosmetic talc causes mesothelioma, nor does it resolve the wider scientific debate over asbestos contamination and cancer risk. Its immediate legal finding is narrower: the company did not present sufficient evidence that Emory, Maddox and Kradin published their disputed statements with the level of knowledge or recklessness required to sustain the trade libel claim.
Mesothelioma is an aggressive cancer affecting the lining surrounding organs, most commonly the lungs, and asbestos exposure is its principal established cause. Litigation involving cosmetic talc has focused heavily on allegations that some talc deposits or finished products contained asbestos fibres. Johnson & Johnson has consistently disputed claims that its products contained asbestos.
The ruling arrives as the company seeks to reduce its exposure to more than a decade of talc litigation. Johnson & Johnson announced in July a proposed settlement committing at least $5.5 billion to resolve about 76,000 ovarian cancer claims. The agreement requires participation by firms representing at least 95 per cent of the remaining claims before it can take effect.
The settlement follows three unsuccessful attempts to resolve large numbers of talc claims through bankruptcy proceedings involving subsidiaries. A bankruptcy judge rejected the latest restructuring plan in 2025, after which Johnson & Johnson returned to defending cases individually while pursuing challenges to plaintiffs’ expert testimony.